Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma.
Department of Medical Oncology, Cukurova University Faculty of Medicine, Balcali, Adana, Turkey. sepay@cu.edu.tr.
Semra
S
Paydas
Department of Medical Oncology, Cukurova University Faculty of Medicine, Balcali, Adana, Turkey.
Ali
A
Ogul
Cem
C
Mirili
Department of Medical Oncology, Cukurova University Faculty of Medicine, Balcali, Adana, Turkey.
Cem
C
Irili
Department of Medical Oncology, Cukurova University Faculty of Medicine, Balcali, Adana, Turkey.
Serkan
S
Gokcay
D000079963:Brentuximab Vedotin; D019008:Drug Resistance, Neoplasm; D006689:Hodgkin Disease / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007565:Jaundice / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D018796:Immunoconjugates; D000079963:Brentuximab Vedotin